Can-Fite BioPharma Ltd.
-34.7% · 90d
$2.92
+0.01 (+0.34%)
After-Hours $2.92(-0.02)
News
(1)April 2026
Can-Fite BioPharma Ltd. — 424B3 Filing
CANFCan-Fite BioPharma Ltd.
# 🧾 What This Document Is This is a **prospectus**, specifically Form 424B3. Think of it as a detailed sales document required by the SEC. Its main purpose isn't for Can-Fite to raise new money, but to **allow existing shareholders (the "selling shareholders") to resell up to 3.29 million ordinary
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%